Rhenman & Partners Asset Management Ab Adverum Biotechnologies, Inc. Put Options Transaction History
Rhenman & Partners Asset Management Ab
- $1.01 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ADVM
# of Institutions
4Shares Held
2.53MCall Options Held
0Put Options Held
0-
Tcg Crossover Management, LLC Palo Alto, CA2.01MShares$14.7 Million2.06% of portfolio
-
Versant Venture Management, LLC San Francisco, CA507KShares$3.7 Million7.72% of portfolio
-
Pinz Capital Management, LP New York, NY15.7KShares$114,6100.03% of portfolio
-
American Portfolios Advisors Holbrook, NY1.15KShares$8,3950.0% of portfolio
About Adverum Biotechnologies, Inc.
- Ticker ADVM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 99,333,600
- Market Cap $725M
- Description
- Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...